Ipamorelin vs GHRP-2: Ghrelin-Receptor Selectivity, Structure and Which to Use

Ipamorelin and GHRP-2 target the same receptor — GHS-R1a, the growth hormone secretagogue receptor that also binds ghrelin — yet their selectivity differs, and that difference is really the only reason to prefer one over the other. GHRP-2 derives from the enkephalin-based GHRP-6 scaffold and is reported to shift cortisol, prolactin and appetite signalling as well as growth hormone, whereas ipamorelin was specifically described as giving a relatively isolated GH response in animal studies. So when weighing ipamorelin against GHRP-2, the key question is whether any of your readouts would be muddied by that wider neuroendocrine activity.

We supply both as lyophilized powder with lot-matched HPLC certificates — ipamorelin in 2, 5 and 10 mg vials, GHRP-2 in 5 and 10 mg vials — and both are listed under GHRPs and secretagogues. Each is a research chemical intended solely for in-vitro and preclinical laboratory work.

Common pharmacophore, different ends

Align the sequences and the kinship is clear. Each contains D-2-naphthylalanine and D-phenylalanine, and each ends in Lys-NH2. D-2-Nal is the substitution that sets potency across the GHRP family — it is why GHRP-2 is more potent than its parent GHRP-6 scaffold — while the C-terminal amide removes the negative charge a free carboxyl end would carry, helping both receptor binding and resistance to carboxypeptidases.

They diverge at the N-terminus and in chain length. GHRP-2 starts with D-alanine, which hinders aminopeptidase cleavage, and has alanine and tryptophan inserted mid-chain for a total of six residues. Ipamorelin instead starts with alpha-aminoisobutyric acid, a non-proteinogenic residue that both restricts backbone conformation and resists proteolysis, and presents the same pharmacophore in only five residues.

Both, therefore, are compact, protease-resistant molecules with straightforward synthesis, but ipamorelin is the smaller and more conformationally restricted ligand. Its molecular weight of 711.85 g/mol versus 817.97 g/mol for GHRP-2 also means that one milligram of ipamorelin contains roughly 15 percent more molecules — enough to skew any comparison made on a weight basis.

Selectivity: where the real difference lies

GHS-R1a operates inside a neuroendocrine network that overlaps with the hypothalamic–pituitary–adrenal axis, prolactin secretion and appetite control. Earlier GH secretagogues, including GHRP-6, hexarelin and GHRP-2, were reported to cause measurable changes in cortisol, ACTH and prolactin in addition to GH release — and, for the GHRP-6 lineage, in food intake too.

Ipamorelin was profiled precisely against that backdrop. The animal studies introducing it highlighted a GH response lacking the cortisol and prolactin shifts produced by the earlier compounds, and it was this reported selectivity that turned it into a standard tool for separating GHS-R1a signalling from the rest of the neuroendocrine picture.

Two caveats apply. First, such selectivity claims come from animal and cell studies and are relative, not absolute — "comparatively clean" does not mean "free of off-target effects at every concentration". Second, GHRP-2's wider profile is not a flaw. When the research question concerns how secretagogue signalling interacts with the HPA axis or with appetite regulation, the broader compound is the informative one, and ipamorelin would reveal nothing.

Place in the literature and what each is best used for

GHRP-2 holds a particular place in the history of the field: it helped establish the growth hormone secretagogue receptor as a target separate from the GHRH receptor, years before ghrelin was found to be its natural ligand. That pedigree makes it a practical reference agonist — used to characterise GHS-R1a binding, to calibrate calcium-flux and inositol-phosphate assays, and, together with GHRP-6 and hexarelin, to anchor potency comparisons across the family. In certain jurisdictions it also has a regulatory history as a diagnostic agent for testing GH secretion, though that concerns the regulated pharmaceutical product, not research-grade powder.

Ipamorelin plays another role. It is chosen when a study requires GHS-R1a activation without the confounding signals, which is why it is the more frequent partner for GHRH analogues in combination experiments — two separate receptors, two arms of the somatotropic axis. For such designs we carry CJC-1295 co-formulated with ipamorelin and ipamorelin co-formulated with GHRP-2, plus CJC-1295 (No DAC) on its own for single-component arms. Our article on the GH secretagogue landscape maps the entire family.

Matching the compound to the research question

Pick ipamorelin when the readout has to stay uncontaminated

Where a study measures GH output, downstream IGF-1 or GHS-R1a signalling itself, and changes in cortisol, prolactin or feeding would act as confounders, ipamorelin's reported selectivity is exactly what it offers. It is also the right secretagogue arm in a two-receptor combination study, where an off-target signal could not be attributed to either compound.

Pick GHRP-2 when the wider profile is what you are studying

When the question involves how secretagogue signalling relates to the HPA axis, prolactin secretion or appetite pathways, GHRP-2 activates the very systems you want to measure. It is also the better benchmark for calibrating potency across the family and for reproducing older secretagogue studies, many of which used it.

Use both when selectivity is the variable under test

Together the two form a clean two-point selectivity series: identical receptor, common pharmacophore, differing reported breadth of off-target activity. Testing them side by side with a complete endocrine panel — not just GH — is the accepted way to verify a selectivity claim rather than simply accept it. Adding GHRP-6 or hexarelin lengthens the series; the ipamorelin vs GHRP-6 and hexarelin vs ipamorelin guides cover those comparisons.

Differences in handling, reconstitution and storage

Both are short amidated peptides containing unnatural residues, and both are relatively easy to handle: there are no lipid chains, free thiols or reactive linkers. One standard protocol serves for each — keep sealed lyophilized vials frozen, let them reach room temperature before piercing the stopper so that moisture does not condense on the cold powder, add diluent down the side of the vial, dissolve without shaking and aliquot so the stock is not frozen and thawed repeatedly. Our reconstitution guide and storage guide give the details.

One difference needs specific mention. GHRP-2 has a tryptophan at position 4, and tryptophan is the amino acid most vulnerable to photo-oxidation in peptides; it breaks down under light, especially in aqueous solution with dissolved oxygen or trace metals present. Keep GHRP-2 solutions protected from light and make them up fairly fresh. Ipamorelin has no tryptophan and is relatively insensitive to light, although its naphthylalanine is still aromatic, so extended exposure to strong light is best avoided for both.

Concentration is a bench calculation, not a usage recommendation: a 5 mg vial made up with 2 mL of diluent gives 2.5 mg/mL (2,500 mcg/mL), so 0.1 mL holds 250 mcg. Since the molecular weights differ by around 15 percent, equal mass concentrations do not give equal molarities, and potency comparisons should be prepared and reported in molar units.

Purity, identity and certificate checks

Obtain the lot-matched certificate for every vial and confirm HPLC purity with a visible chromatogram, a mass-spectrometry result agreeing with the expected molecular weight — 711.85 g/mol for ipamorelin, 817.97 g/mol for GHRP-2 — and a lot number identical to the vial label. Two checks are particular to this pair. Both peptides are amidated at the C-terminus; a free-acid impurity differs by 1 Da, elutes close to the main peak and behaves as a different molecule at the receptor, so amidation must be verified, not presumed. Both also contain D-amino acids, and epimerisation during synthesis creates diastereomers with the same mass that mass spectrometry cannot resolve — which is why a chromatogram showing one sharp peak counts for more here than the purity percentage. For GHRP-2, a satellite peak 16 Da above the parent can signal tryptophan oxidation in older material. Our COA guide describes what a complete certificate should include.

Regulatory position

Ipamorelin and GHRP-2 are supplied as research chemicals for laboratory use only and are not for human consumption. Neither is an approved medicine in the United States. GHRP-2 has been regulated as a diagnostic agent in some jurisdictions, but that status belongs to a regulated pharmaceutical product, not to research-grade powder. For wider context, see our growth and performance research overview.